Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-12-02
2010-12-14
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S327000, C424S001690
Reexamination Certificate
active
07851444
ABSTRACT:
An isolated, synthetic or recombinant χ-conotoxin peptide comprising the following sequence of amino acids: Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof. The invention also relates to pharmaceutical compositions comprising these peptides and the use of these peptides in the prophylaxis or treatment of conditions, such as but not limited to, pain, inflammation, incontinence, cardiovascular conditions and mood disorders.
REFERENCES:
patent: 5587454 (1996-12-01), Justice et al.
patent: 6767896 (2004-07-01), McIntosh et al.
patent: 6794361 (2004-09-01), Lewis et al.
patent: 7326682 (2008-02-01), Lewis et al.
patent: 2003/0170222 (2003-09-01), Jones et al.
patent: 2004/0176278 (2004-09-01), Jones et al.
patent: 2005/0054827 (2005-03-01), Lewis et al.
patent: 2005/0271589 (2005-12-01), Jones et al.
patent: 2009/0088389 (2009-04-01), Lewis et al.
patent: 2009/0275498 (2009-11-01), Lewis et al.
patent: WO 91/07980 (1991-06-01), None
patent: WO 96/14079 (1996-05-01), None
patent: WO 96/40064 (1996-12-01), None
patent: WO 97/01351 (1997-01-01), None
patent: WO 97/30997 (1997-08-01), None
patent: WO 98/02148 (1998-01-01), None
patent: WO 98/05309 (1998-02-01), None
patent: WO 98/22126 (1998-05-01), None
patent: WO 98/51668 (1998-11-01), None
patent: WO 00/20444 (2000-04-01), None
patent: WO 00/44769 (2000-08-01), None
Balaji et al. 2000, J. Biol. Chem. 275(50): 39516-39522.
Bowersox, S.S. et al., “Selective N-Type Neuronal Voltage-Sensitive Calcium Channel Blocker, SNX-111, Produces Spinal Antinociception in rat Models of Acute, Persistent and Neuropathic Pain”, J. Pharmacol Exp. Ther., 279 (3): 1243-1249 (1996).
Krames, Elliot S. et al., “Intrathecal D-Ala2-D-Leu5-enkephalin (DADL) Restores Analgesia in a Patient Analgetically Tolerant to Intrathecal Morphine Sulfate”, Pain, 24: 205-209 (1986).
Takagi, H. et al., “Analgesic Effect of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Patients with Chronic Pain”, European Neuropsychopharmacology, 6: 43-47 (1996).
Eisenach, C. et al., “Cerebrospinal Fluid Norepinephrine and Acetylcholine Concentrations During Acute Pain”, Anesth Analg, 82: 621-626 (1996).
Dubner, R. et al., “The Neurobiology of Pain and Its Modulation”, The Clinical Journal of Pain, 5(Suppl 2): S1-S6 (1989).
Dyck, P.J et al., “New Understanding and Treatment of Diabetic Neuropathy”, The New England Journal of Medicine, 326(19):1287-1288(1992).
Atkinson, J. H. et al., “A Placebo-controlled Randomized Clinical Trial of Nortriptyline for Chronic Low Back Pain”, Pain, 76: 287-296 (1998).
Mico, J. A., et al., “Analgesic, Sedative and Antidepressent Effects of Noradrenergic Antidepressants Related to Beta-Adrenoceptors”, European Neuropsychopharmacology, S162, p. 1.086, Abstract (1997).
Springer, J. P. et al., “Facilitatory and Inhibitory Effects of Selective Norephinephrine Reuptake Inhibitors on Hypogastric Nerve-Evoked Urethral Contractions in the Cat: A Prominent Role of Urethral S-Adrenergic Receptors”, The Journal of Urology, 152: 515-519 (1984).
Diann, T. G. et al., “Assessment of Central Noradrenergic Functioning in Irritable Bowel Syndrome Using a Neuroendocrine Challenge Test”, Journal of Psychosomatic Research, 34(5): 575-580 (1990).
Leung, D. et al., “Protease Inhibitors: Current Status and Future Prospects”, J. Med Chem, 43(3): 305-341 (2000).
O'Neill, M. J. et al., “Effects of Ca2+ and Na+ channel inhibitors in vitro and inn global cerebal ischaemia in vivo”, European Journal of Pharmacology, 332: 121-131 (1997).
Eisenach, J. C. et al., “Intrathecal, but Not Intravenous, Clonidine Reduces Experimental Thermal or Capsaicin-Induced Pain and Hyperalgesia in Normal Volunteers”, Anesth Analg, 87:591-596 (1998).
Marban, E. et al., “Structure and Function of Voltage-Gated Sodium Channels”, Journal of Physiology, 508.3: 647-657 (1998).
Yanagawa, Y. et al., “A Novel Sodium Channel Inhibitor from Conus geographus: Purification, Structure, and Pharmacological Properties”, Biochemistry, 27: 6256-6262 (1988).
Ryan, R., et al., “Evaluation of an Enkephalin Analog in Men with Castor Oil-Induced Diarrhea”, Clinical Pharmacol Ther, 39(1): 40-42 (1986).
Penttila, O, et al., “Studies of Rectal Mucosal Catecholamines in Ulcerative Colitis”, Annals of Clinical Research, 7: 32-36 (1975).
Alewood Dianne
Alewood Paul Francis
Lewis Richard James
Palant Elka
Audet Maury
Schully, Scott, Murphy & Presser, P.C.
Xenome Ltd.
LandOfFree
χ-conotoxin peptides (-1) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with χ-conotoxin peptides (-1), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and χ-conotoxin peptides (-1) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184773